Behind The Knife: The Surgery Podcast cover image

Journal Review in Breast Surgery: Management of Hereditary Breast Cancer

Behind The Knife: The Surgery Podcast

00:00

The Benefits of Endocrine Therapy for High Risk Genes

Not a lot of women that are BRCA2 positive are going to want to get randomized to either bilateral mastectomy or tamoxifen. In the carrier study for the patients who had a Pout B2 mutation, the lifetime risk of developing breast cancer was 32%. So if you cut that by 40%, I can't exactly do the math, but you get into like 15 to 18% risk, lifetime risk. Non-mutation carrier, lifetime risk would be 12%. so you do get almost two kind of normal risk and certainly below that threshold of high risk.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app